Zongertinib-Hernexeos Price Analysis and Formal Purchasing Channel Guide

Zongertinib (trade name: Hernexeos) is a tyrosine kinase inhibitor that targets HER2 (ERBB2). Oral small molecule targeted drugs with mutations in the amino acid kinase domain (TKD) are mainly used to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC). It achieves anti-tumor effects by selectively inhibiting the HER2 signaling pathway and blocking cancer cell proliferation and metastasis. The research and development of Hernexeos fills the treatment gap for HER2 TKD mutated lung cancer patients and provides a new treatment option for refractory patients.

In terms of price, as of August 2025, the retail price of Hernexeos in the U.S. market is approximately $9,800 per month. Because the drug is a newly launched targeted drug, its research and development costs are high and the patient population is relatively limited, so the price is on the high side. It has not yet been officially launched in China, and there is currently no official pricing or medical insurance reimbursement policy. If patients want to use Hernexeos, they need to participate in clinical trials or purchase it through overseas formal channels, and they must bear the full cost of the drug.

As for purchase channels, patients can obtain HernexeosHernexeos in China mainly through two channels: one is to participate in ongoing clinical trials and provide drugs through hospitals; the other is to obtain original drugs through regular overseas pharmacies or cross-border medical services. When purchasing overseas, patients need to pay attention to drug transportation conditions, customs policies and storage requirements to ensure drug safety and efficacy. It should be emphasized that there are currently no generic drugs on the market, so you can only choose original drugs to obtain them.

In general, zongatinib (Hernexeos), as a new generation of HER2 targeted drugs, has brought new treatment options to patients with specific mutations of NSCLC. However, since it is not yet on the market in China and is expensive, patients should give priority to regular channels when using it and conduct individualized medication under the guidance of professional doctors. At the same time, attention should be paid to the future marketing dynamics of drugs and medical insurance policies, so that treatment can be obtained more conveniently and economically when conditions permit.

Reference link:https://www.drugs.com